[
  {
    "nctId": "NCT03073876",
    "title": "Detecting an Early Response to Donepezil With Measures of Visual Attention",
    "briefTitle": "Detecting an Early Response to Donepezil With Measures of Visual Attention",
    "status": "COMPLETED",
    "startDate": "2005-12-01",
    "completionDate": "2021-01-13",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "Donepezil Hydrochloride",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT05741060",
    "title": "Arterial Stiffness, Cognition and Equol",
    "briefTitle": "Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers",
    "status": "ACTIVE_NOT_RECRUITING",
    "startDate": "2023-06-29",
    "completionDate": "2027-01-30",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "S-equol",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Arterial Stiffness",
      "White Matter Lesions",
      "Cognitive Decline"
    ]
  },
  {
    "nctId": "NCT00547560",
    "title": "An Ascending Multiple Dose Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of GSI-953 Administered Orally To Healthy Elderly Subjects",
    "briefTitle": "Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population",
    "status": "COMPLETED",
    "startDate": "2007-08",
    "completionDate": "2009-10",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "GSI-953"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Healthy"
    ]
  },
  {
    "nctId": "NCT00556660",
    "title": "",
    "briefTitle": "Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects",
    "status": "COMPLETED",
    "startDate": "2007-09",
    "completionDate": "2008-07",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "[123I] AV-151"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT02016560",
    "title": "An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease",
    "briefTitle": "Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects",
    "status": "COMPLETED",
    "startDate": "2013-12",
    "completionDate": "2017-07-28",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      "florbetapir F 18",
      "Flortaucipir F18"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT04251182",
    "title": "A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects With Mild-to-Moderate Alzheimer's Disease",
    "briefTitle": "Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects",
    "status": "COMPLETED",
    "startDate": "2021-03-01",
    "completionDate": "2023-02-17",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "15mg T3D-959",
      "30 mg T3D-959",
      "45 mg T3D-959",
      "Placebos"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT03393520",
    "title": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",
    "briefTitle": "Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",
    "status": "COMPLETED",
    "startDate": "2017-10-13",
    "completionDate": "2023-12-14",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Placebo",
      "AVP-786"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Agitation in Patients With Dementia of the Alzheimer's Type"
    ]
  },
  {
    "nctId": "NCT05227820",
    "title": "Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias",
    "briefTitle": "Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia",
    "status": "COMPLETED",
    "startDate": "2022-01-19",
    "completionDate": "2022-08-20",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "NE3107"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT01565382",
    "title": "Evaluation of Physician Training for Interpretation of Florbetapir-PET Scans: Evaluation of Inter-reader Reliability Using Images From Subjects With a Clinical Presentation of AD or MCI",
    "briefTitle": "Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)",
    "status": "COMPLETED",
    "startDate": "2011-02",
    "completionDate": "2011-02",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "florbetapir F 18"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00000173",
    "title": "A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)",
    "briefTitle": "Memory Impairment Study (Mild Cognitive Impairment Study)",
    "status": "COMPLETED",
    "startDate": "1999-03",
    "completionDate": "2004-01",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Donepezil",
      "Vitamin E"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT00931073",
    "title": "A Phase I, Open-Label, Three-Period, Fixed-Sequence Study To Estimate The Steady-State Effect Of Ketoconazole And Omeprazole On The Single-Dose Pharmacokinetics Of Dimebon [PF-01913539] In Healthy CYP2D6 EM And PM Subjects",
    "briefTitle": "A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers",
    "status": "COMPLETED",
    "startDate": "2009-07",
    "completionDate": "2009-10",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "Dimebon alone",
      "Dimebon + Ketoconazole",
      "Dimebon + Omeprazole"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Huntington's Disease"
    ]
  },
  {
    "nctId": "NCT02035982",
    "title": "A Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease in Long Term Care Setting",
    "briefTitle": "Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2010-07",
    "completionDate": "2015-09",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Cholinesterase Inhibitor",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Dementia"
    ]
  },
  {
    "nctId": "NCT04619420",
    "title": "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease",
    "briefTitle": "A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "startDate": "2021-01-06",
    "completionDate": "2032-12-30",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "JNJ-63733657",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Cognitive Dysfunction",
      "Dementia"
    ]
  },
  {
    "nctId": "NCT01662882",
    "title": "An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",
    "briefTitle": "A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)",
    "status": "COMPLETED",
    "startDate": "2012-10",
    "completionDate": "2013-02",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      "florbetapir (18F)"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Mild Cognitive Impairment"
    ]
  },
  {
    "nctId": "NCT02997982",
    "title": "Feasibility and Effects on Markers in Spinal Fluid in Persons With Early Alzheimer's Disease When Treated With Valaciclovir - Open Fas II Pilot Study (VALZ-Pilot)",
    "briefTitle": "Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2016-12",
    "completionDate": "2020-03-04",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Valaciclovir 500Mg Tablet"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Mild Cognitive Impairment",
      "Herpes Simplex"
    ]
  },
  {
    "nctId": "NCT05269173",
    "title": "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Mild and Moderate Alzheimer's Disease",
    "briefTitle": "Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2020-10-29",
    "completionDate": "2024-11-05",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Flos gossypii flavonoids tablet"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT02719327",
    "title": "Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults",
    "briefTitle": "Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid",
    "status": "COMPLETED",
    "startDate": "2017-06-08",
    "completionDate": "2023-09-29",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      "icosapent ethyl (IPE)"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT01672827",
    "title": "A Study to Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images.",
    "briefTitle": "Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images",
    "status": "COMPLETED",
    "startDate": "2012-07",
    "completionDate": "2012-08",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "[18F]Flutemetamol"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Mild Cognitive Impairment"
    ]
  },
  {
    "nctId": "NCT03518073",
    "title": "Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease",
    "briefTitle": "A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2018-04-30",
    "completionDate": "2021-10-25",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Zagotenemab",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease (AD)"
    ]
  },
  {
    "nctId": "NCT05468073",
    "title": "Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD",
    "briefTitle": "Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD",
    "status": "RECRUITING",
    "startDate": "2022-10-11",
    "completionDate": "2026-09-01",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Proleukin",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT04396873",
    "title": "Phase 1 Study: PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease",
    "briefTitle": "PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease",
    "status": "RECRUITING",
    "startDate": "2021-08-17",
    "completionDate": "2030-10-03",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "11C-MC1",
      "11C-PS13",
      "18f-florbetaben"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Parkinson's Disease",
      "Dementia",
      "Alzheimer's Disease",
      "ALS",
      "Mild Cognitive Impairment"
    ]
  },
  {
    "nctId": "NCT00842673",
    "title": "A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease",
    "briefTitle": "Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2009-02",
    "completionDate": "2010-09",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "ST101",
      "ST101",
      "ST101",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT06384573",
    "title": "The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) Amyloid Removal Trial (ART): A Phase IIIb/IV Open-Label Study of Lecanemab to Evaluate Prevention and Progression of Dominantly Inherited Alzheimer's Disease",
    "briefTitle": "DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease",
    "status": "RECRUITING",
    "startDate": "2024-06-10",
    "completionDate": "2030-06",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "lecanemab"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Dementia",
      "Alzheimer's Disease, Familial"
    ]
  },
  {
    "nctId": "NCT06335173",
    "title": "A Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Intravenous Sabirnetug in Early Alzheimer's Disease",
    "briefTitle": "A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants with Early Alzheimer's Disease (ALTITUDE-AD)",
    "status": "ACTIVE_NOT_RECRUITING",
    "startDate": "2024-02-29",
    "completionDate": "2026-10",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "sabirnetug",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT01827982",
    "title": "A Double-Blind, Placebo-Controlled, Randomized, Single-Ascending Dose Study To Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Subjects",
    "briefTitle": "A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo",
    "status": "COMPLETED",
    "startDate": "2013-03",
    "completionDate": "2013-07",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "JNJ-54861911 1mg",
      "JNJ-54861911 3 mg",
      "JNJ-54861911 9 mg",
      "JNJ-54861911 27 mg",
      "JNJ-54861911 81 mg",
      "JNJ-54861911 160 mg",
      "JNJ-54861911 tbd",
      "JNJ-54861911 9 mg",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Healthy"
    ]
  },
  {
    "nctId": "NCT02380573",
    "title": "Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",
    "briefTitle": "Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2015-07",
    "completionDate": "2023-07",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Methylene Blue",
      "FD&C Blue # 2",
      "Phenazopyridine hydrochloride"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Mild Cognitive Impairment",
      "MCI",
      "Aging",
      "Alzheimer's Disease",
      "AD"
    ]
  },
  {
    "nctId": "NCT00417482",
    "title": "Antipsychotic Discontinuation in Alzheimer's Disease",
    "briefTitle": "Antipsychotic Discontinuation in Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2004-08",
    "completionDate": "2011-04",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "risperidone"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Psychotic Disorders",
      "Agitation",
      "Aggression"
    ]
  },
  {
    "nctId": "NCT00329082",
    "title": "LY2062430: Multiple-Dose Safety in Subjects With Mild-to-Moderate Alzheimer's Disease and Single-Dose Safety in Healthy Volunteers",
    "briefTitle": "Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers",
    "status": "COMPLETED",
    "startDate": "2006-05",
    "completionDate": "2008-05",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "LY2062430",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT03493282",
    "title": "A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease",
    "briefTitle": "Effect of CT1812 Treatment on Brain Synaptic Density",
    "status": "COMPLETED",
    "startDate": "2018-03-28",
    "completionDate": "2020-10-16",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      "Active Treatment- CT1812 100 mg",
      "Active Treatment- CT1812 300 mg",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT05361382",
    "title": "Longitudinal Multicenter Head-to-Head Harmonization of Tau PET Tracers",
    "briefTitle": "Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease",
    "status": "ACTIVE_NOT_RECRUITING",
    "startDate": "2021-11-23",
    "completionDate": "2027-05-31",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "18F-Flortaucipir radiopharmaceutical",
      "18F-MK-6240 radiopharmaceutical",
      "Amyloid-\u03b2 radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Florbetapir)"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT04770220",
    "title": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype",
    "briefTitle": "An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects",
    "status": "COMPLETED",
    "startDate": "2021-05-19",
    "completionDate": "2024-07-29",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Experimental: ALZ-801",
      "Placebo Comparator: Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Early Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT02336360",
    "title": "A Multicenter Study to Obtain Data to Assist in Radiation Dosimetry Calculations From Subjects Enrolled in Human Studies Employing 18F-AV-1451",
    "briefTitle": "Augmenting Flortaucipir Dosimetry Estimates",
    "status": "COMPLETED",
    "startDate": "2015-01",
    "completionDate": "2015-06",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "Flortaucipir F18"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT06223360",
    "title": "A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)",
    "briefTitle": "A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)",
    "status": "RECRUITING",
    "startDate": "2024-03-22",
    "completionDate": "2027-12-01",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Low Dose Benfotiamine",
      "High Dose Benfotiamine",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT01438060",
    "title": "A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type",
    "briefTitle": "Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type",
    "status": "COMPLETED",
    "startDate": "2000-08",
    "completionDate": "2010-07",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Aripiprazole (BMS-337039)",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Dementia, Alzheimer Type"
    ]
  },
  {
    "nctId": "NCT02127476",
    "title": "A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease",
    "briefTitle": "A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2014-07",
    "completionDate": "2017-05",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "KHK6640",
      "Matching Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00000176",
    "title": "Alzheimer's Disease Prevention Trial. A Multi-center, Randomized, Double-blind Placebo Controlled Trial of Estrogens to Prevent Alzheimer's Disease and Loss of Memory in Women.",
    "briefTitle": "Alzheimer's Disease Prevention Trial",
    "status": "COMPLETED",
    "startDate": "",
    "completionDate": "2007-09",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Estrogen",
      "Estrogen and Progesterone"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Memory Disorders"
    ]
  },
  {
    "nctId": "NCT05469360",
    "title": "A Randomized, Participant and Investigator Blinded, Placebo-Controlled Study to Evaluate the Ability of a Single Intrathecally Administered Dose of NIO752 to Lower Cerebrospinal Fluid Total Tau Levels in Participants With Early Alzheimer's Disease",
    "briefTitle": "Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants",
    "status": "RECRUITING",
    "startDate": "2023-02-23",
    "completionDate": "2027-11-07",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "NIO752",
      "NIO752",
      "Matching placebo",
      "NIO752",
      "NIO752",
      "NIO752",
      "Matching placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Mild Cognitive Impairment"
    ]
  },
  {
    "nctId": "NCT04149860",
    "title": "Interventional, Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease",
    "briefTitle": "Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2019-09-27",
    "completionDate": "2023-07-19",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "Lu AF87908",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Healthy",
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT01265394",
    "title": "A Single-arm, Open-label, Multi-center Study to Determine the Specificity of Flutemetamol (18F) Injection for Excluding the Presence of Brain Amyloid in Healthy Young Adult Subjects Aged 18 to 40",
    "briefTitle": "Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects",
    "status": "COMPLETED",
    "startDate": "2010-12",
    "completionDate": "2011-04",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "[18F] Flutemetamol"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Healthy"
    ]
  },
  {
    "nctId": "NCT01741194",
    "title": "A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension",
    "briefTitle": "AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext",
    "status": "COMPLETED",
    "startDate": "2013-03",
    "completionDate": "2017-04-14",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      "AC-1204",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT03451591",
    "title": "LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease.",
    "briefTitle": "LACunar Intervention (LACI-2) Trial-2",
    "status": "COMPLETED",
    "startDate": "2018-01-08",
    "completionDate": "2022-08-11",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      "Isosorbide Mononitrate XL (ISMN)",
      "Cilostazol",
      "ISMN XL and Cilostazol"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Cerebral Small Vessel Diseases",
      "Stroke, Lacunar"
    ]
  },
  {
    "nctId": "NCT05657691",
    "title": "XanaCIDD: A Double-Blind, Randomized, Placebo Controlled, Parallel-Group Trial to Assess the Safety, Tolerability, and Efficacy of Xanamem\u00ae in Adults With Major Depressive Disorder and Impaired Cognition",
    "briefTitle": "Xanamem\u00ae in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)",
    "status": "COMPLETED",
    "startDate": "2022-11-28",
    "completionDate": "2024-07-01",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Xanamem\u2122",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Major Depressive Disorder",
      "MDD",
      "Cognitive Impairment"
    ]
  },
  {
    "nctId": "NCT00803894",
    "title": "A Randomized Clinical Trial to Study the Effects of MK0752 Versus Placebo on Biomarkers in Healthy Young Adult Male Subjects",
    "briefTitle": "A Clinical Study to Determine Biomarkers of Response to a Gamma Secretase Inhibitor",
    "status": "COMPLETED",
    "startDate": "2008-12",
    "completionDate": "2009-01",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "MK0752",
      "Comparator: MK0752.",
      "Comparator: Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Healthy"
    ]
  },
  {
    "nctId": "NCT00906191",
    "title": "An Open-Label, Single-Dose, Nonrandomized Study Of The Mass Balance And Metabolic Disposition Of Orally Administered 14C-Labeled SAM-531 In Healthy Male Subjects",
    "briefTitle": "Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects",
    "status": "COMPLETED",
    "startDate": "2009-05",
    "completionDate": "2009-08",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "SAM-531"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT00420420",
    "title": "A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of MK0249 for the Symptomatic Treatment of Alzheimer's Disease",
    "briefTitle": "MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)",
    "status": "COMPLETED",
    "startDate": "2006-11",
    "completionDate": "2008-08",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "MK0249",
      "Comparator: Placebo (unspecified)"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00203320",
    "title": "Etanercept for Alzheimer's-Type Memory Loss Pilot Study II",
    "briefTitle": "TNF-Alpha Inhibition for Treatment of Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2005-04",
    "completionDate": "2006-01",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "etanercept given by perispinal administration"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00750282",
    "title": "An Open-label, Non-randomized, Multi-center Study to Optimize Image Assessment and Evaluate the Efficacy and Safety of BAY 94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection/Exclusion of Cerebral Amyloid Beta in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers",
    "briefTitle": "Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral \u03b2-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers",
    "status": "COMPLETED",
    "startDate": "2008-08",
    "completionDate": "2010-11",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Florbetaben (BAY94-9172)"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Amyloid Beta-Protein"
    ]
  },
  {
    "nctId": "NCT00495820",
    "title": "Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study",
    "briefTitle": "Methylphenidate for Apathy in Alzheimer's Dementia: A Controlled Study",
    "status": "COMPLETED",
    "startDate": "2007-08",
    "completionDate": "2010-06",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "Methylphenidate"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Apathy",
      "Dementia"
    ]
  },
  {
    "nctId": "NCT02351882",
    "title": "Safety and Efficacy of Nabilone in Alzheimer's Disease: a Pilot Study",
    "briefTitle": "Safety and Efficacy of Nabilone in Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2015-01",
    "completionDate": "2019-03",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      "Nabilone",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Agitation",
      "Weight Loss",
      "Pain",
      "Oxidative Stress"
    ]
  },
  {
    "nctId": "NCT00100282",
    "title": "Single Dose Escalation Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease",
    "briefTitle": "Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2003-05",
    "completionDate": "2005-06",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "PPI-1019 (APAN)"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT02646982",
    "title": "Candesartan's Effects on Alzheimer's Disease And Related Biomarkers",
    "briefTitle": "Candesartan's Effects on Alzheimer's Disease And Related Biomarkers",
    "status": "COMPLETED",
    "startDate": "2016-06-30",
    "completionDate": "2020-08-17",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Placebo",
      "Candesartan"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Mild Cognitive Impairment"
    ]
  },
  {
    "nctId": "NCT00018382",
    "title": "Insulin, Neurogenetics and Memory in Alzheimer's Disease: A Novel Therapeutic Approach",
    "briefTitle": "Insulin, Neurogenetics and Memory in Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "1999-10",
    "completionDate": "2003-03",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "rosiglitazone"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT00403520",
    "title": "Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders",
    "briefTitle": "Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers",
    "status": "COMPLETED",
    "startDate": "2006-11",
    "completionDate": "2010-08",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "Experimental 1",
      "Placebo Comparator"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT04118920",
    "title": "Safety of Topical Insulin Eye Drops for the Treatment of Open-angle Glaucoma",
    "briefTitle": "Safety of Topical Insulin Drops for Open-angle Glaucoma",
    "status": "ACTIVE_NOT_RECRUITING",
    "startDate": "2023-03-27",
    "completionDate": "2024-12",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "Topical insulin (4 units)",
      "Topical insulin (20 units)",
      "Artificial tears"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Glaucoma"
    ]
  },
  {
    "nctId": "NCT02187627",
    "title": "Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Tau Imaging With Positron Emission Tomography in Healthy Control Subjects and Subjects With Alzheimer's Disease",
    "briefTitle": "Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants",
    "status": "COMPLETED",
    "startDate": "2014-08-31",
    "completionDate": "2016-02-29",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "[11C]RO6924963",
      "[11C]RO6931643",
      "[18F]RO6958948"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease, Healthy Volunteer"
    ]
  },
  {
    "nctId": "NCT01661673",
    "title": "Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease",
    "briefTitle": "Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2012-11",
    "completionDate": "",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "EVP-0962",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Mild Cognitive Impairment",
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT01254773",
    "title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects With Mild to Moderate Alzheimer's Disease",
    "briefTitle": "Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2010-12",
    "completionDate": "2013-03",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Experimental Bapineuzumab"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00407576",
    "title": "PET Imaging of Brain Amyloid Using [11C]MeS-IMPY",
    "briefTitle": "PET Imaging of Brain Amyloid Using [11C]MeS-IMPY",
    "status": "COMPLETED",
    "startDate": "2006-12-01",
    "completionDate": "",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "[11C]MeS-IMPY"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Healthy"
    ]
  },
  {
    "nctId": "NCT00024531",
    "title": "Effect of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium, Lipitor, in the Treatment of Alzheimer's Disease",
    "briefTitle": "Lipitor as a Treatment for Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2000-10",
    "completionDate": "2004-08",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Atorvastatin calcium"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT01539031",
    "title": "Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease",
    "briefTitle": "Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2012-03",
    "completionDate": "2015-03",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "E2020",
      "E2020"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Type Dementia"
    ]
  },
  {
    "nctId": "NCT05077631",
    "title": "A Phase I, Double-Blind, Placebo-controlled, Randomized Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics in Healthy Adults",
    "briefTitle": "Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics",
    "status": "COMPLETED",
    "startDate": "2021-02-15",
    "completionDate": "2022-02-22",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "ACD856",
      "Placebo",
      "ACD856 (fed cohort)"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Cognition Disorder"
    ]
  },
  {
    "nctId": "NCT00261573",
    "title": "The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia",
    "briefTitle": "A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia",
    "status": "COMPLETED",
    "startDate": "1998-12",
    "completionDate": "2000-12",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "galantamine hydrobromide"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Vascular Dementia"
    ]
  },
  {
    "nctId": "NCT00112073",
    "title": "A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 in Patients With Mild to Moderate AD",
    "briefTitle": "AAB-001 in Patients With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2005-04",
    "completionDate": "2008-12",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "bapineuzumab"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT04747431",
    "title": "A Phase 1b Open-Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacodynamic Effects of a Single Dose of PBFT02 Delivered Into the ICM of Adults With FTD and Mutations in the GRN or C9ORF72 Genes",
    "briefTitle": "A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes",
    "status": "RECRUITING",
    "startDate": "2021-09-14",
    "completionDate": "2031-08",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      "PBFT02"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Frontotemporal Dementia",
      "FTD",
      "FTD-GRN",
      "Dementia Frontotemporal",
      "C9orf72"
    ]
  },
  {
    "nctId": "NCT04044131",
    "title": "A Phase 2, Randomized, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) And Parkinson's Disease (PD) Patients",
    "briefTitle": "Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients",
    "status": "COMPLETED",
    "startDate": "2019-12-02",
    "completionDate": "2021-04-20",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Metabolic Cofactor Supplementation",
      "Sorbitol"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Parkinson Disease"
    ]
  },
  {
    "nctId": "NCT06297590",
    "title": "A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3954068 in Patients With Early Symptomatic Alzheimer's Disease",
    "briefTitle": "A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease",
    "status": "RECRUITING",
    "startDate": "2024-08-15",
    "completionDate": "2027-02",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "LY3954068",
      "Placebo",
      "Flortaucipir F18"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT05456503",
    "title": "Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Disease Using the PET Ligand PI-2620",
    "briefTitle": "PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620",
    "status": "RECRUITING",
    "startDate": "2022-09-19",
    "completionDate": "2028-08",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "FPI-2620"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Frontotemporal Lobar Degeneration",
      "Alzheimer Disease",
      "Cognitively Normal"
    ]
  },
  {
    "nctId": "NCT02239003",
    "title": "",
    "briefTitle": "NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment",
    "status": "COMPLETED",
    "startDate": "2012-01",
    "completionDate": "2017-12",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "DAOIB",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Mild Cognitive Impairment"
    ]
  },
  {
    "nctId": "NCT03402503",
    "title": "A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease",
    "briefTitle": "Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2018-11-26",
    "completionDate": "2024-04-03",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Montelukast buccal film"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT00205179",
    "title": "Alzheimer's Disease: Potential Benefit of Isoflavones",
    "briefTitle": "Alzheimer's Disease: Potential Benefit of Isoflavones",
    "status": "COMPLETED",
    "startDate": "2005-01",
    "completionDate": "2009-12",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Novasoy",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00385684",
    "title": "Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)",
    "briefTitle": "Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)",
    "status": "COMPLETED",
    "startDate": "2007-10",
    "completionDate": "2014-06",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "hydrocodone/APAP w placebo PRN",
      "hydrocodone/APAP",
      "placebo with hydrocodone/APAP PRN"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Dementia",
      "Dementia, Vascular",
      "Pain"
    ]
  },
  {
    "nctId": "NCT01174290",
    "title": "Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study",
    "briefTitle": "Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol",
    "status": "COMPLETED",
    "startDate": "2010-09",
    "completionDate": "2014-03",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "Haloperidol decanoate",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Subsyndromal Delirium"
    ]
  },
  {
    "nctId": "NCT02051790",
    "title": "Evaluation of Reader Training Processes by Comparing Clinical Interpretations to Centralized Expert Reads",
    "briefTitle": "Evaluation of Reader Training Processes",
    "status": "COMPLETED",
    "startDate": "2014-03",
    "completionDate": "2014-08",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "florbetapir F 18"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT04476303",
    "title": "A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of BEY2153 After Oral Administration in Healthy Young and Elderly Male Volunteers.",
    "briefTitle": "A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants",
    "status": "COMPLETED",
    "startDate": "2020-08-27",
    "completionDate": "2021-11-23",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "BEY2153"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00010803",
    "title": "Ginkgo Biloba Prevention Trial in Older Individuals",
    "briefTitle": "Ginkgo Biloba Prevention Trial in Older Individuals",
    "status": "COMPLETED",
    "startDate": "2000-10",
    "completionDate": "2011-07",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Ginkgo biloba",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Dementia",
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT03367403",
    "title": "Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease",
    "briefTitle": "A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)",
    "status": "COMPLETED",
    "startDate": "2017-12-18",
    "completionDate": "2021-09-21",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Donanemab",
      "Placebo",
      "LY3202626"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT04902703",
    "title": "Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease (SESAD)",
    "briefTitle": "Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease",
    "status": "RECRUITING",
    "startDate": "2022-06-01",
    "completionDate": "2026-10-31",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Sargramostim",
      "Saline - placebo comparator"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT06185543",
    "title": "A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease (AD)",
    "briefTitle": "A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.",
    "status": "RECRUITING",
    "startDate": "2023-11-19",
    "completionDate": "2025-11",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "PrimeC",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT02167594",
    "title": "18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers",
    "briefTitle": "Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers",
    "status": "COMPLETED",
    "startDate": "2014-08-12",
    "completionDate": "2016-07-11",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "Flortaucipir F18"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Progressive Supranuclear Palsy",
      "Corticobasal Degeneration"
    ]
  },
  {
    "nctId": "NCT02103894",
    "title": "Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects",
    "briefTitle": "Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects",
    "status": "COMPLETED",
    "startDate": "2014-02",
    "completionDate": "2016-09",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "[18F]T807 ([18F]MNI-777)"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease (AD)",
      "Parkinson's Disease (PD)",
      "Chronic Traumatic Encephalopathy (CTE)",
      "Progressive Supranuclear Palsy (PSP)",
      "Frontal Temporal Dementia (FTD)",
      "Pick's Disease",
      "Tauopathies"
    ]
  },
  {
    "nctId": "NCT05269394",
    "title": "A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease",
    "briefTitle": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)",
    "status": "ACTIVE_NOT_RECRUITING",
    "startDate": "2021-12-22",
    "completionDate": "2028-07",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      "E2814",
      "Lecanemab",
      "Matching Placebo (E2814)"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimers Disease",
      "Dementia",
      "Alzheimers Disease, Familial"
    ]
  },
  {
    "nctId": "NCT01202994",
    "title": "Practice Effects and Amyloid Imaging Using 18F-PIB (18F-39-F-6-OH-BTA1) Known as [18FGE067]) or Flutemetamol PET and FDG-PET",
    "briefTitle": "Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET",
    "status": "COMPLETED",
    "startDate": "2011-05",
    "completionDate": "2020-10-14",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "18F-Flutemetamol"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT01039194",
    "title": "A Study of the Effect of Concomitant Administration of Multiple Doses of BMS-708163 on the Pharmacokinetics of Galantamine in Healthy Subjects",
    "briefTitle": "Drug-Drug Interaction to Study the Effect of BMS-708163 on Pharmacokinetics (PK) of Galantamine Extended Release (ER)",
    "status": "COMPLETED",
    "startDate": "2010-01",
    "completionDate": "2010-04",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "galantamine",
      "galantamine",
      "BMS-708163"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT00719394",
    "title": "Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI-136 Administered Orally to Healthy Japanese Male Subjects and Healthy Japanese Elderly Male Subjects",
    "briefTitle": "Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males",
    "status": "COMPLETED",
    "startDate": "2008-03",
    "completionDate": "2008-08",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "GSI 136",
      "placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Healthy"
    ]
  },
  {
    "nctId": "NCT02886494",
    "title": "A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia",
    "briefTitle": "A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia",
    "status": "COMPLETED",
    "startDate": "2016-12",
    "completionDate": "2018-11-01",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "BAC treatment",
      "Matched vehicle"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease or Vascular Dementia"
    ]
  },
  {
    "nctId": "NCT05318976",
    "title": "A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation",
    "briefTitle": "A Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation",
    "status": "ACTIVE_NOT_RECRUITING",
    "startDate": "2022-02-28",
    "completionDate": "2025-05-15",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "XPro1595",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Dementia",
      "Brain Diseases",
      "Central Nervous System Diseases",
      "Nervous System Diseases",
      "Tauopathies",
      "Neurodegenerative Diseases",
      "Neurocognitive Disorders",
      "Mental Disorders",
      "Mild Cognitive Impairment"
    ]
  },
  {
    "nctId": "NCT03789760",
    "title": "A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel, and Multi-centre Study to Evaluate the Clinical Efficacy and Safety of SaiLuoTong (SLT) in the Treatment of Vascular Dementia",
    "briefTitle": "The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule",
    "status": "COMPLETED",
    "startDate": "2019-04-10",
    "completionDate": "2024-05-19",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "SaiLuoTong capsule",
      "placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Vascular Dementia"
    ]
  },
  {
    "nctId": "NCT00745576",
    "title": "An Open-label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Verapamil Immediate Release (IR) and a Single Dose of SAM-531 When Co-administered Orally to Healthy Young Adult Subjects",
    "briefTitle": "Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered",
    "status": "COMPLETED",
    "startDate": "2008-10",
    "completionDate": "2008-12",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "SAM-531"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT01054976",
    "title": "The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease",
    "briefTitle": "The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2006-10",
    "completionDate": "2009-02",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "Galantamine"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT03944460",
    "title": "A Randomized, Double-blind and Placebo-controlled Single Ascending-dose Phase I Study (First-in-human) to Investigate the Safety, Tolerability and Pharmacokinetics of Contraloid Acetate (in Healthy Subjects).",
    "briefTitle": "SAD Phase I Study (First-in-human) to Investigate Contraloid Acetate",
    "status": "COMPLETED",
    "startDate": "2018-04-09",
    "completionDate": "2018-07-27",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "Contraloid"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Dementia",
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT03277573",
    "title": "A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease",
    "briefTitle": "Salsalate in Patients Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2017-07-21",
    "completionDate": "2023-04-10",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "Salsalate",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT05647473",
    "title": "Efficacy, Safety and Response Predictors of Adjuvant Astragalus for Cognition in Alzheimer Disease With Orthostatic Hypotension: an add-on, Assessor-blind, Pragmatic Randomized Controlled Trial",
    "briefTitle": "Efficacy, Safety and Response Predictors of Adjuvant Astragalus for Cognition in Orthostatic Hypotension",
    "status": "RECRUITING",
    "startDate": "2024-02-20",
    "completionDate": "2025-05-30",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "add-on low dose Astragalus",
      "add-on high dose Astragalus"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Orthostatic Hypotension",
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT02103673",
    "title": "",
    "briefTitle": "DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia",
    "status": "COMPLETED",
    "startDate": "2014-02",
    "completionDate": "2017-11",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "DAOIB",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Behavioral and Psychological Symptoms in Alzheimer's Disease",
      "Behavioral and Psychological Symptoms in Vascular Dementia"
    ]
  },
  {
    "nctId": "NCT01453127",
    "title": "DaTSCAN Imaging in Aging and Neurodegenerative Disease",
    "briefTitle": "DaTSCAN Imaging in Aging and Neurodegenerative Disease",
    "status": "ENROLLING_BY_INVITATION",
    "startDate": "2011-10",
    "completionDate": "2025-12",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Dementia",
      "Parkinsonism",
      "Mild Cognitive Impairment",
      "REM Sleep Behavior Disorder"
    ]
  },
  {
    "nctId": "NCT03503331",
    "title": "UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy",
    "briefTitle": "UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy",
    "status": "RECRUITING",
    "startDate": "2018-04-20",
    "completionDate": "2026-04-01",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "[C-11]PiB-PET/MRI"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT00257673",
    "title": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of MEM 1003 in Patients With Mild to Moderate Alzheimer's Disease",
    "briefTitle": "Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2005-11",
    "completionDate": "2007-10",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "MEM 1003",
      "MEM 1003",
      "Placebo for MEM 1003"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00253227",
    "title": "Galantamine in the Treatment of Alzheimer's Disease: Flexible Dose Range Trial",
    "briefTitle": "A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "1997-07",
    "completionDate": "1998-12",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "galantamine hydrobromide"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Dementia"
    ]
  },
  {
    "nctId": "NCT00096473",
    "title": "A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period",
    "briefTitle": "Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2001-01",
    "completionDate": "2005-09",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Donepezil hydrochloride"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Dementia"
    ]
  },
  {
    "nctId": "NCT02094729",
    "title": "A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",
    "briefTitle": "A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2013-09",
    "completionDate": "2015-05",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "BAN2401 2.5 mg/kg",
      "BAN2401 5 mg/kg",
      "BAN2401 10 mg/kg",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00304629",
    "title": "Long Term Safety and Efficacy of Galantamine in Alzheimer's Disease (Extension INT-8)",
    "briefTitle": "Long-term Safety and Efficacy of Galantamine in Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2000-03",
    "completionDate": "2002-03",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "galantamine"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT00940589",
    "title": "A Double-blind, Parallel Group, Randomized, Placebo Controlled Study of the Efficacy of Circadin\u00ae 2mg in Patients With Mild to Moderate Alzheimer Disease (AD) Treated With Acetylcholinesterase (AChE) Inhibitor",
    "briefTitle": "Efficacy of Circadin\u00ae 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor",
    "status": "COMPLETED",
    "startDate": "2009-09",
    "completionDate": "2013-05",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Circadin",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Sleep Disorder"
    ]
  },
  {
    "nctId": "NCT03186989",
    "title": "A Randomized, Double-Blind, Placebo-Controlled Study, Followed by an Open-Label Extension, to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease",
    "briefTitle": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2017-10-12",
    "completionDate": "2022-05-12",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "IONIS MAPTRx"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Mild Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00750529",
    "title": "Effects of Galantamine and Don\u00e9p\u00e9zil on the Amount and the Quality oh the Sleep in Patients Suffering From Alzheimer Disease.",
    "briefTitle": "Alzheimer and Sleep",
    "status": "COMPLETED",
    "startDate": "2008-11",
    "completionDate": "2013-09",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "Galantamine and Donepezil"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00007189",
    "title": "Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)",
    "briefTitle": "Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)",
    "status": "COMPLETED",
    "startDate": "2001-01",
    "completionDate": "",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Naproxen Sodium (Aleve)",
      "Celecoxib (Celebrex)"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT02795780",
    "title": "An Open Label, Multicenter Study Evaluating the Imaging Characteristics of a Follow up 18F-AV-1451 Scan in Subjects That Participated in the Confirmatory Cohort of 18F-AV-1451-A05",
    "briefTitle": "Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05",
    "status": "COMPLETED",
    "startDate": "2016-08",
    "completionDate": "2017-08-28",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Flortaucipir F18"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT05822362",
    "title": "Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial",
    "briefTitle": "CBD for Individuals at Risk for Alzheimer's Disease",
    "status": "RECRUITING",
    "startDate": "2024-01-19",
    "completionDate": "2029-04",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Cannabidiol"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Mild Cognitive Impairment"
    ]
  },
  {
    "nctId": "NCT00035191",
    "title": "A Randomized 26-Week, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia",
    "briefTitle": "A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia",
    "status": "COMPLETED",
    "startDate": "2001-10",
    "completionDate": "2003-09",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "galantamine"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Dementia, Vascular"
    ]
  },
  {
    "nctId": "NCT02005991",
    "title": "A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects",
    "briefTitle": "A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377",
    "status": "COMPLETED",
    "startDate": "2013-11",
    "completionDate": "2014-01",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "PF-05212377",
      "PF-05212377",
      "PF-05212377"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Healthy"
    ]
  },
  {
    "nctId": "NCT01354691",
    "title": "A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease",
    "briefTitle": "Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2011-02",
    "completionDate": "2013-03",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "ladostigil hemitartrate"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Dementia",
      "Memory Loss",
      "Cognitive Impairment"
    ]
  },
  {
    "nctId": "NCT01005862",
    "title": "A Randomized, Investigator And Subject-Blind, Sponsor-Open, Placebo-Controlled Study To Examine The Effects Of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers",
    "briefTitle": "Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers",
    "status": "COMPLETED",
    "startDate": "2010-03",
    "completionDate": "2012-09",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT02434666",
    "title": "Safety and Tolerability of CPC-201 in Patients With Dementia of the Alzheimer's Type Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07",
    "briefTitle": "Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07",
    "status": "COMPLETED",
    "startDate": "2015-01-08",
    "completionDate": "2016-11-22",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "CPC-201"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Dementia of the Alzheimer's Type"
    ]
  },
  {
    "nctId": "NCT00966966",
    "title": "An Open-Label, Nonrandomized Study To Evaluate The Potential Pharmacokinetic Interaction Between SAM-531 and Gemfibrozil, A Cytochrome P-450 2C8 Inhibitor, When Coadministered Orally To Healthy Young Adult Subjects",
    "briefTitle": "Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered",
    "status": "COMPLETED",
    "startDate": "2009-09",
    "completionDate": "2009-12",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "SAM-531 and gemfibrozil"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Healthy"
    ]
  },
  {
    "nctId": "NCT01333865",
    "title": "A Study of Memantine Hydrochloride (Namenda\u00ae) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders",
    "briefTitle": "A Study of Memantine Hydrochloride (Namenda\u00ae) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders",
    "status": "COMPLETED",
    "startDate": "2010-01",
    "completionDate": "2014-07",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "Memantine"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Autism Spectrum Disorders"
    ]
  },
  {
    "nctId": "NCT02914366",
    "title": "Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia",
    "briefTitle": "Ambroxol as a Treatment for Parkinson's Disease Dementia",
    "status": "ACTIVE_NOT_RECRUITING",
    "startDate": "2015-11",
    "completionDate": "2025-12",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Ambroxol"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Parkinson's Disease Dementia"
    ]
  },
  {
    "nctId": "NCT02442765",
    "title": "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",
    "briefTitle": "Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type",
    "status": "COMPLETED",
    "startDate": "2015-07-23",
    "completionDate": "2019-02-27",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "AVP-786",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Agitation in Patients With Dementia of the Alzheimer's Type"
    ]
  },
  {
    "nctId": "NCT01966666",
    "title": "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI-287 in Patients With Mild to Moderate Alzheimer's Disease",
    "briefTitle": "A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2013-11",
    "completionDate": "2019-09",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "TPI-287 2 mg/m2",
      "TPI-287 6.3 mg/m2",
      "TPI-287 20 mg/m2",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT04538066",
    "title": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing Safety, Tolerability and Long-term Efficacy of Bryostatin in the Treatment of Moderately Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment",
    "briefTitle": "Bryostatin Treatment of Moderately Severe Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2020-08-30",
    "completionDate": "2022-11-16",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Bryostatin 1"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT00283920",
    "title": "PET Imaging of Brain Peripheral Type Benzodiazepine Receptors",
    "briefTitle": "PET Imaging of Brain Peripheral Benzodiazepine Receptors",
    "status": "COMPLETED",
    "startDate": "2006-01-26",
    "completionDate": "2007-10-02",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "[(11)C] PBR28"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Healthy Volunteer"
    ]
  },
  {
    "nctId": "NCT00829374",
    "title": "CONCERT: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Twelve-Month Safety and Efficacy Study Evaluating Dimebon in Patients With Mild-to-Moderate Alzheimer's Disease on Donepezil",
    "briefTitle": "Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil",
    "status": "COMPLETED",
    "startDate": "2009-03",
    "completionDate": "2011-12",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Dimebon",
      "Dimebon",
      "Placebo comparator"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT01492374",
    "title": "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",
    "briefTitle": "Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2012-02",
    "completionDate": "2013-10",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "BMS-241027",
      "BMS-241027",
      "BMS-241027",
      "Placebo matching BMS-241027"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT00545974",
    "title": "A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia",
    "briefTitle": "Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia",
    "status": "COMPLETED",
    "startDate": "2007-10",
    "completionDate": "2012-12",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "memantine",
      "Placebo pill"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Frontal Lobe Dementia",
      "Frontotemporal Lobe Dementia",
      "Semantic Dementia"
    ]
  },
  {
    "nctId": "NCT04592874",
    "title": "A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease",
    "briefTitle": "A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2021-01-22",
    "completionDate": "2024-09-12",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "AL002",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT00236574",
    "title": "A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer's Disease.",
    "briefTitle": "A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment",
    "status": "COMPLETED",
    "startDate": "2001-05",
    "completionDate": "2003-11",
    "phases": [
      "PHASE3"
    ],
    "interventions": [
      "Galantamine hydrobromide"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Dementia",
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT02260674",
    "title": "A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects With Early Alzheimer's Disease",
    "briefTitle": "A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2014-11",
    "completionDate": "2016-06",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "JNJ-54861911, 10 milligram (mg)",
      "JNJ-54861911, 50 mg",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease"
    ]
  },
  {
    "nctId": "NCT01110720",
    "title": "A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy",
    "briefTitle": "Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy",
    "status": "COMPLETED",
    "startDate": "2010-10",
    "completionDate": "2012-12",
    "phases": [
      "PHASE2",
      "PHASE3"
    ],
    "interventions": [
      "Davunetide",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Progressive Supranuclear Palsy"
    ]
  },
  {
    "nctId": "NCT01928420",
    "title": "A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease",
    "briefTitle": "A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2007-04",
    "completionDate": "2014-06",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Drug: NIC5-15",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Alzheimer's Disease",
      "Dementia"
    ]
  },
  {
    "nctId": "NCT01518374",
    "title": "Clinical Evaluation of Florbetapir F 18 (18F-AV-45)",
    "briefTitle": "Clinical Evaluation of Florbetapir F 18 (18F-AV-45)",
    "status": "COMPLETED",
    "startDate": "2009-12",
    "completionDate": "2017-05-03",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "Florbetapir F 18"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease",
      "Mild Cognitive Impairment",
      "Neurodegenerative Diseases"
    ]
  },
  {
    "nctId": "NCT04871074",
    "title": "SV2A PET Imaging in Alzheimer's Disease",
    "briefTitle": "The Synapse Project",
    "status": "ACTIVE_NOT_RECRUITING",
    "startDate": "2018-11-18",
    "completionDate": "2025-05",
    "phases": [
      "PHASE2"
    ],
    "interventions": [
      "UCB-J"
    ],
    "interventionTypes": [
      "DRUG"
    ],
    "conditions": [
      "Alzheimer Disease"
    ]
  },
  {
    "nctId": "NCT04685265",
    "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of anle138b, and to Characterise the Effect of Food of anle138b in Mild to Moderate Parkinson's Disease",
    "briefTitle": "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease",
    "status": "COMPLETED",
    "startDate": "2020-12-22",
    "completionDate": "2022-12-22",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "anle138b",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Parkinson Disease"
    ]
  },
  {
    "nctId": "NCT01780974",
    "title": "Pilot Study: Lipoic Acid and Omega-3 Fatty Acid for Alzheimer's Disease Prevention",
    "briefTitle": "Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention",
    "status": "COMPLETED",
    "startDate": "2013-04",
    "completionDate": "2015-10",
    "phases": [
      "PHASE1",
      "PHASE2"
    ],
    "interventions": [
      "Lipoic Acid plus Omega-3 Fatty Acids",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Treated Hypertension"
    ]
  },
  {
    "nctId": "NCT01461174",
    "title": "Effects of 15-day Donepezil and Memantine on Cognitive Functions After a 24 Hours Sleep Deprivation Challenge in Healthy Volunteers: a Double-blind, Placebo-controlled, Randomised, Cross-over Study, With Modafinil as Positive Control",
    "briefTitle": "Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers",
    "status": "COMPLETED",
    "startDate": "2011-11",
    "completionDate": "2014-11",
    "phases": [
      "PHASE1"
    ],
    "interventions": [
      "Modafinil",
      "Donepezil",
      "Memantine"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Healthy"
    ]
  },
  {
    "nctId": "NCT02087865",
    "title": "Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease",
    "briefTitle": "Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease",
    "status": "COMPLETED",
    "startDate": "2014-05",
    "completionDate": "2021-12-20",
    "phases": [
      "PHASE4"
    ],
    "interventions": [
      "donepezil HCL",
      "Placebo"
    ],
    "interventionTypes": [
      "DRUG",
      "DRUG"
    ],
    "conditions": [
      "Genetic Risk for Alzheimer's Disease"
    ]
  }
]